Last updated 2026-06-18
- Went public, Aug 2024
- Raised $10M funding round, Apr 2014
- Raised $6M grant, Sep 2009
Total raised
$27.6M
Last: 2025-01
Stage
Public
Founded
2008
Headcount
31
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences
About
Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. The company conducted phase 2 clinical trial with its first generation product which has shown positive efficacy results vs the control of chemotherapy alone.
Silexion’s commitment to pushing the boundaries of therapeutic advancements in the field of oncology, is focused in enhancing its first-generation product (LODERTM) to develop a new formulated product which will improve the clinical efficacy that Silexion observed with its first-generation product against pancreatic cancer.
With a strong foundation in RNA interference technology, Silexion Therapeutics develops innovative RNA-based therapeutics designed to silence specific genes involved in pancreatic cancer growth and metastasis. By selectively suppressing these genes, it aims to disrupt tumor progression and enhance the therapeutic response.
Funding history · 4 rounds · $27.6M total
2025-01
$3.3M
2015-10
$2.4M
2014-04
$10.0M
2009-09
Grant
$6.0M
Q&A
- What is Silexion Therapeutics' primary focus?
- Silexion Therapeutics is a developmental stage company dedicated to developing innovative treatments for pancreatic cancer, utilizing RNA interference technology to silence genes involved in cancer growth and metastasis.
- When did Silexion Therapeutics become publicly traded and on what exchange?
- Silexion Therapeutics became publicly traded on NASDAQ in August 2024, following a business combination with Moringa Acquisition Corp.
- What significant preclinical results did Silexion Therapeutics announce for SIL204 in September 2025?
- In September 2025, Silexion Therapeutics announced positive preclinical results for its RNA interference therapy, SIL204, demonstrating high inhibition rates (83.5% to 99.7%) across eleven human cancer cell lines with various KRAS mutations, including the first evidence of activity in gastric cancer.
- What strategic partnership did Silexion Therapeutics form in September 2025?
- In September 2025, Silexion Therapeutics announced a strategic partnership with AMS Advanced Medical Services GmbH, a contract research organization, to support its upcoming Phase 2/3 clinical trials for SIL204, targeting KRAS-driven solid tumor cancers.
- What was the outcome of Silexion Therapeutics' toxicology studies for SIL204 in November 2025?
- In November 2025, Silexion Therapeutics successfully completed toxicology studies for its RNA interference therapy, SIL204, confirming no systemic organ toxicity. This allows the company to proceed with regulatory submissions for a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026.
- What was the purpose of the 1-for-9 reverse share split announced by Silexion Therapeutics in November 2024?
- In November 2024, Silexion Therapeutics announced a 1-for-9 reverse share split of its ordinary shares, effective November 27, 2024, to comply with NASDAQ requirements, maintain its listing, and support strategic growth initiatives.
- What collaboration did Silexion Therapeutics announce in December 2024?
- In December 2024, Silexion Therapeutics announced a collaboration with Evonik to develop an advanced siRNA formulation using Evonik's biodegradable PLGA microparticle formulation for Silexion's siRNA candidate, SIL-204, aimed at improving cancer treatment efficacy.
- What was the outcome of Silexion Therapeutics' warrant exercise in January 2025?
- In January 2025, Silexion Therapeutics announced the exercise of outstanding warrants, generating approximately $3.3 million in gross proceeds, which will be used as working capital for general corporate purposes.
- What preclinical data did Silexion Therapeutics report in January 2025 regarding SIL-204?
- In January 2025, Silexion Therapeutics reported promising preclinical data for its siRNA therapeutic candidate, SIL-204, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models through systemic administration.
- What is the employee count for Silexion Therapeutics?
- Silexion Therapeutics has an employee count in the 11-50 range.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
drug-discoverybiological-therapycanceroncologydrug-deliverypharmaceuticalscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | silexion.com/ |
|---|
Identifiers & details
| Former names | Silenseed |
|---|---|
| Founded | 2008-11 |
| Employees (exact) | 31 |
| Market cap | $6.0M |
| Status reason | Public on NASDAQ on Aug, 2024; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2024-08 | ||||
| 2025-09 | $6.0M |